Antibody and cytokine study for people with CGD
Part of Blood & lymphatic, Genetic & congenital, Immune system & allergy clinical trials.
This study is checking levels of antibodies and immune-signaling molecules (cytokines) in people with chronic granulomatous disease (CGD). It aims to better understand the immune system in CGD, which may help with future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of chronic granulomatous disease (CGD).
- Your CGD diagnosis must be based on a specific lab test showing very low NADPH oxidase activity or a confirmed gene mutation.
- You or your legal guardian must be able to sign a consent form.
- You must be able to follow the study rules and give blood samples as needed.
- You cannot have had a bone marrow transplant or gene therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the immune system works in people who have abnormal immune function, often shown by unusual or repeated infections or long-lasting inflammation. It may involve tests using blood samples and storage of blood for future research.
This trial tests a new gene therapy for X-linked chronic granulomatous disease (CGD), a condition where the immune system cannot fight certain infections. The treatment uses your own blood stem cells, which are modified in the lab to help your body produce working immune cells.
This trial tests a new gene-editing treatment for men with a specific genetic mutation that causes X-linked chronic granulomatous disease (CGD). The goal is to fix the faulty gene in your own blood stem cells to help your immune system fight infections better.
This trial tests an intensive stem cell transplant approach for people with chronic granulomatous disease (CGD). The study aims to improve outcomes by preparing the body for a donor stem cell graft and using immune “brakes” to reduce immune problems.
This trial tests a lentiviral gene therapy to improve immune function in people with CGD, a condition where the body can’t fight certain infections well. It may help by addressing the underlying genetic problem, but it also requires a procedure to collect immune cells and special “conditioning” medicines beforehand.
This trial tests a new gene editing treatment called PM359 for people with a specific type of chronic granulomatous disease (CGD) caused by a delGT mutation in the NCF1 gene. The goal is to see if it's safe and helps fight infections and inflammation.
Hear when a new Chronic Granulomatous Disease (CGD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.